Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Therapeutic Testosterone

Review the clinical trials studying therapeutic testosterone on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Status: Active
Location: 12 locations
Sequential High Dose Testosterone and Enzalutamide Compared with Enzalutamide Alone for the Treatment of Asymptomatic Metastatic Castration Resistant Prostate Cancer, STEP-UP Study
Status: Active
Location: 11 locations
Bipolar Androgen Therapy in Combination with Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 4 locations
Bipolar Androgen Therapy and Radium-223 for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, MAT-RAD Trial
Status: Active
Location: 2 locations
Testosterone Replacement in Male Cancer Survivors with Fatigue and Low Testosterone
Status: Active
Location: 2 locations
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Eflornithine and Testosterone Followed by Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, APEX Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients with Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men with Localized Prostate Cancer on Active Surveillance
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Testosterone Replacement Therapy in Improving Quality of Life in Prostate Cancer Survivors with Androgen Deficiency
Status: Active
Location: 3 locations
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Status: Active
Location: 2 locations
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients with Low Testosterone
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia